Higher Fludarabine and Cyclophosphamide Exposures Lead to Worse Outcomes in Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Adult Hematologic Malignancy.

Adolescent Adult Cyclophosphamide Hematologic Neoplasms / therapy Hematopoietic Stem Cell Transplantation Humans Vidarabine / analogs & derivatives
Noncompartmental analysis Pharmacodynamic Pharmacokinetic Phosphoramide mustard Reduced-intensity conditioning

Journal

Transplantation and cellular therapy
ISSN: 2666-6367
Titre abrégé: Transplant Cell Ther
Pays: United States
ID NLM: 101774629

Informations de publication

Date de publication:
09 2021
Historique:
received: 15 02 2021
revised: 28 04 2021
accepted: 13 05 2021
pubmed: 28 5 2021
medline: 15 10 2021
entrez: 27 5 2021
Statut: ppublish

Résumé

Reduced-intensity conditioning regimens using fludarabine (Flu) and cyclophosphamide (Cy) have been widely used in hematopoietic cell transplantation (HCT) recipients. The optimal exposure of these agents remains to be determined. We aimed to delineate the exposure-outcome associations of Flu and Cy separately and then both combined on HCT outcomes. This is a single-center, observational, pharmacokinetic (PK)-pharmacodynamic (PD) study of Flu and Cy in HCT recipients age ≥18 years who received Cy (50 mg/kg in a single dose), Flu (150 to 200 mg/m

Identifiants

DOI: 10.1016/j.jtct.2021.05.013 PMID: 34044184 PMC: PMC8627667
pubmed: 34044184
pii: S2666-6367(21)00932-5
doi: 10.1016/j.jtct.2021.05.013
pmc: PMC8627667
mid: NIHMS1749711
pii:
doi:

Substances chimiques

Cyclophosphamide 8N3DW7272P
Vidarabine FA2DM6879K
fludarabine P2K93U8740

Types de publication

Journal Article Observational Study Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

773.e1-773.e8

Subventions

Organisme : NCI NIH HHS
ID : P01 CA065493
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA077598
Pays : United States

Informations de copyright

Copyright © 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Références

Bone Marrow Transplant. 2011 Jan;46(1):20-6
pubmed: 20383215
Clin Cancer Res. 2006 Aug 15;12(16):4888-98
pubmed: 16914577
Blood. 2003 Mar 1;101(5):2043-8
pubmed: 12406916
Biol Blood Marrow Transplant. 2016 Nov;22(11):1915-1925
pubmed: 27481448
Clin Pharmacol Ther. 2005 Sep;78(3):298-308
pubmed: 16153400
Biol Blood Marrow Transplant. 2017 Oct;23(10):1701-1713
pubmed: 28684371
Ther Drug Monit. 2005 Dec;27(6):756-65
pubmed: 16306851
J Chromatogr B Biomed Sci Appl. 2000 Aug 18;745(2):345-55
pubmed: 11043753
Semin Oncol. 1993 Oct;20(5 Suppl 7):2-12
pubmed: 8235690
Lancet Haematol. 2016 Nov;3(11):e526-e536
pubmed: 27746112
Transl Res. 2016 Sep;175:103-115.e4
pubmed: 27094990
Biol Blood Marrow Transplant. 2007 Jul;13(7):853-62
pubmed: 17580264
Bone Marrow Transplant. 2012 Sep;47(9):1178-85
pubmed: 22231460
Haematologica. 2016 May;101(5):521-30
pubmed: 27132278
Cancer Chemother Pharmacol. 2015 Jul;76(1):85-96
pubmed: 25983023
Biol Blood Marrow Transplant. 2015 Apr;21(4):761-7
pubmed: 25585275
Clin Pharmacol Ther. 2009 Jun;85(6):615-22
pubmed: 19295506
Clin Pharmacokinet. 2019 May;58(5):627-637
pubmed: 30327943
Eur J Cancer. 2011 Jul;47(10):1556-63
pubmed: 21482104
Front Pharmacol. 2020 Apr 23;11:406
pubmed: 32390827
Expert Opin Drug Metab Toxicol. 2017 Sep;13(9):901-923
pubmed: 28766962
Clin Pharmacokinet. 2005;44(11):1135-64
pubmed: 16231966
Ann Oncol. 2002 Mar;13(3):374-84
pubmed: 11996467
Eur J Cancer. 2016 Mar;55:56-64
pubmed: 26773420
Blood Adv. 2019 Jul 23;3(14):2179-2187
pubmed: 31324638
Rapid Commun Mass Spectrom. 2005;19(24):3673-80
pubmed: 16287039
Bone Marrow Transplant. 2019 Feb;54(2):284-292
pubmed: 29915216
Clin Cancer Res. 2020 Apr 1;26(7):1563-1573
pubmed: 31796512
Clin Pharmacol Ther. 2004 Sep;76(3):270-80
pubmed: 15371987
Eur J Clin Pharmacol. 2013 Aug;69(8):1543-51
pubmed: 23588565

Auteurs

Takuto Takahashi (T)

Division of Pediatric Hematology/Oncology/Blood and Marrow Transplant, University of Minnesota, Minneapolis, Minnesota; Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota.

Aileen Scheibner (A)

Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota.

Qing Cao (Q)

Biostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.

Rachael Pearson (R)

Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota.

Kinjal Sanghavi (K)

Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota.

Daniel J Weisdorf (DJ)

Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.

Claudio G Brunstein (CG)

Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.

John Rogosheske (J)

Department of Pharmacy, M Health Fairview, Minneapolis, Minnesota.

Veronika Bachanova (V)

Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.

Erica D Warlick (ED)

Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.

Anthony Wiseman (A)

University of Minnesota Medical School, Minneapolis, Minnesota.

Pamala A Jacobson (PA)

Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota. Electronic address: jacob117@umn.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adolescent › Higher Fludarabine and Cyclophosphamide...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Higher Fludarabine and Cyclophosphamide...
questionsmedicales.fr › Composés chimiques organiques › Composés organiques du phosphore › Phosphoramides › Moutardes phosphoramide › Cyclophosphamide › Higher Fludarabine and Cyclophosphamide...
questionsmedicales.fr › Hémopathies et maladies lymphatiques › Hémopathies › Tumeurs hématologiques › Higher Fludarabine and Cyclophosphamide...
questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation cellulaire › Transplantation de cellules souches › Transplantation de cellules souches hématopoïétiques › Higher Fludarabine and Cyclophosphamide...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Higher Fludarabine and Cyclophosphamide...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléosides › Nucléoside purique › Vidarabine › Higher Fludarabine and Cyclophosphamide...